Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Retrospect and prospect of hematopoietic stem cell transplantation

Prospective of hematopoietic stem cell transplantation

Establish the Hematopoietic Stem Cell Transplantation System with Chinese Characteristics

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Hematopoietic stem cell transplantation:everyone has a donor

Recent advancements in hematopoietic stem cell transplantation in Taiwan

Hematopoietic stem cell transplantation for the treatment of hematological diseases

Current status and prospects of hematopoietic stem cell transplantation in China

Past, Present, and Future Efforts to Enhance the Efficacy of Cord Blood Hematopoietic Cell Transplantation

Hematopoietic Stem Cell Transplantation in China: Current Status and Prospects.

Optimizing Blood Stem Cell Transplants Through Cellular Engineering

Progress in unrelated and haploidentical donor hematopoietic stem cell transplantation :improvement of transplantation model and the latest clinical efficacy

Analysis on expansion potentials and pre-clinical safeties of hematopoietic stem cells from human umbilical cord blood.

Current Status and Development of Hematopoietic Stem Cell Transplantation in China： a Report from Chinese Hematopoietic Stem Cell Transplantation Register Group

Haemopoietic Stem Cell Transplantation--an Evolving Treatment for Severe Autoimmune and Inflammatory Diseases in Rheumatology, Neurology and Gastroenterology.

Optimization of T-cell Replete Haploidentical Hematopoietic Stem Cell Transplantation: the Chinese Experience

Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States

Allogeneic Hematopoietic Stem Cell Transplantation in China: Where We Are and Where to Go

Current Status of Haploidentical Stem Cell Transplantation for Leukemia

Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.